SMS Lifesciences India Limited has informed the Exchange regarding Board meeting held on August 11, 2025.
HALEOSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts more than Nifty Microcap 250 and 0.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
SMS Lifesciences India's Board approved unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025) at its meeting on August 11, 2025. Standalone revenue from operations fell to Rs. 7,904.27 lakhs from Rs. 8,657.06 lakhs a year earlier, an ~8.7% decline, while standalone net profit jumped sharply to Rs. 515.77 lakhs from Rs. 267.51 lakhs, nearly doubling YoY. Consolidated revenue also dipped to Rs. 8,250.46 lakhs, but consolidated net profit rose to Rs. 438.21 lakhs from Rs. 348.27 lakhs (~25.8% growth). Profit growth was driven mainly by lower raw material and other expenses and a reduced tax outflow. The statutory auditor issued an unmodified (clean) limited review opinion on both sets of results. The Board also fixed September 30, 2025 as the date for the 19th AGM via video conferencing and approved certain insider trading and disclosure policies.
Despite a top-line decline, sharply higher profitability signals better cost control and operating leverage, which is positive for shareholders. The clean auditor opinion and AGM scheduling are routine. Short-term stock reaction may hinge on whether the revenue softness is viewed as a one-off or a trend, given the otherwise strong profit print.